Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) is looking for acquisition opportunities. ADMP announced that it intends to offer shares of its common stock in an underwritten public offering. ADMP intends to use the net proceeds of the offering for general corporate purposes, which include, without limitation, hiring additional personnel and other expenditures relating to the company's anticipated commercial launch of its Epinephrine PFS syringe product (if the FDA grants marketing approval for the product), research and development and clinical trial expenditures, acquisitions of new technologies or products, the repayment, refinancing, redemption or repurchase of future indebtedness or capital stock and working capital.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0199 USD | -50.25% |
|
-37.81% | -97.16% |
07-01 | Ebrahim ?Eboo? Versi Separates from His Role as Chief Executive Officer of DMK Pharmaceuticals Corporation | CI |
07-01 | DMK Pharmaceuticals Corporation Announces Management Changes | CI |
1st Jan change | Capi. | |
---|---|---|
-97.16% | 404K | |
+55.96% | 848B | |
+32.47% | 627B | |
-0.38% | 363B | |
+15.03% | 318B | |
+13.37% | 299B | |
+14.70% | 243B | |
+16.58% | 225B | |
+15.94% | 179B | |
+3.35% | 167B |
- Stock Market
- Equities
- DMKPQ Stock
- News DMK Pharmaceuticals Corporation
- ADMP Eyes Acquisitions